SECURITIES AND EXCHANGE COMMISSION

                                             WASHINGTON, D.C. 20549

                                                   FORM 10-QSB
[X]      QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
         SECURITIES EXCHANGE ACT OF 1934
         For the quarterly period ended Sept 31, 2002

[        ] TRANSITION  REPORT  PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
         EXCHANGE ACT OF 1934 for the transition period from  __________________
         to __________________

         Commission File Number 0-23957
         CIK 0001058549

                                                MEDITECNIC, INC.
                        (Exact Name of Registrant as specified in its Charter)


            Delaware                                                87-0430532
(State or other Jurisdiction of                         I.R.S. Employer Identi-
Incorporation or Organization                                     fication No.)

14 Quai du Seujet, Geneva, Switzerland 				    CH-1201
(Address of Principal Executive Offices)                           (Zip Code)

                                                 (949) 489-2400
                           (Registrant's Telephone Number, including Area Code)



         Indicate by check mark whether the Registrant (i) has filed all reports
required to be filed by Section 13, or 15(d) of the  Securities  Exchange Act of
1934  during  the  preceding  12 months  (of for such  shorter  period  that the
Registrant  was required to file such reports) and (ii) has been subject to such
filing requirements for the past 90 days.

                                          Yes    X           No

         Indicate  the  number of  shares  outstanding  of each of the  issuer's
classes of Common Stock, as of the latest practicable date.

Common Stock, $.001 par value                                        7,527,485
- ----------------------------------                       --------------------
Title of Class                                  Number of Shares outstanding
                                                      at Sept 31, 2002
No exhibits included.


                      MEDITECNIC SA


                                    PART F/S

                          Index to Financial Statements

         Report of Certified Public Accountant

Audited Financial Statements for 12 months years ended
  December 31, 2003 and 2002, for MEDITECNIC SA

    Independent Auditor's Report-

      Balance Sheets at 12/31/2003 and 12/31/2002

      Statements of Operations for Yrs 2003 - 2002

      Statements of Cash Flows for Yrs 2003 - 2002

      Statement of Stockholders' Equity from inception (1997 through
        12/31/2003)

      Notes to the Financial Statements





PAGE 2

The Board of Directors
MEDITECNIC INC.
Geneva, Switzerland


                    INDEPENDENT AUDITORS REPORT


I have audited the accompanying balance sheet of MEDITECNIC SA, Geneva,
Switzerland as of December 31, 2003 and 2002, and the related statements
of operations, cash flows, and changes in stockholders equity for the years
then ended.

These financial statements are the responsibility of the Companys management.
My responsibility is to express an opinion on these financial statements
based on my audit.

I conducted my audit in accordance with generally accepted auditing standards.
Those standards require that I plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material
misstatements.  An audit also includes assessing the accounting principles
used and significant estimates made by management, as well as evaluating the
overall financial statement presentation.  I believe that my audit provides a
reasonable basis for my opinion.

In my opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of MEDITECNIC, SA as of December
31, 2003 and 2002, and the results of its operations and cash flows for the
years then ended in conformity with generally accepted accounting principles.




/s/ David M. Winings
-------------------
David M. Winings, C.P.A.
Palm Desert, CA 92211
May 24, 2004









PAGE 3                    MEDITECNIC SA BALANCE SHEET

	                            AUDITED               AUDITED
                                   December 31,          December 31,
              ASSETS                   2003                   2002

CURRENT ASSETS:
Cash and Equivalents              $   81,578            $    9,179
Accounts Receivable (NOTE 2)           7,594               211,806
Inventories (NOTE 3)                 103,365                62,347
Deferred/Unearned Income (NOTE 4)     25,438                22,987
Investments (NOTE 5)                  25,240                32,362
                                    ---------             ---------
   Total current assets            $  243,215            $  338,681
FIXED ASSETS: (NOTE 6)              ---------             ---------
Capitalized/Acquisition Costs     $  195,775            $  160,295
  Less Accumulated Depreciation     < 131,196>           $<  95,759>
                                    ---------             ---------
   Net Fixed Assets                $   64,579            $   64,536
INTANTIBLE ASSETS (NOTE 7)          ---------             ---------
Capitalized Research/Development  $  587,819            $  494,256
  Less Accumulated Amortization     < 454,888>            < 300,061>
                                    ---------             ---------
   Net Intangible Assets           $  132,931            $  194,195
                                    ---------             ---------
TOTAL ASSETS                       $  440,725            $  597,412
                                    =========            ==========
LIABILITIES & SHAREHOLDERS EQUITY
CURRENT LIABILITIES:
Notes and Accounts Payable
  Trade (NOTE 8)                   $   89,671            $   21,376
  Other                                 1,051                     0
Stockholder Current Account(NOTE 9)      -0-                78,664
Prepaid Accrued Liabilities(NOTE10)   18,447                10,623
                                    ---------             ---------
   Total current liabilities       $  109,169            $  110,663
LONG TERM LIABILITIES: (NOTE 11)    ---------             ---------
Postponed Stockholders Loans     $2,512,967            $1,867,749
                                    ---------             ---------
TOTAL LIABILITIES                  $2,622,136            $1,978,412
SHAREHOLDERS EQUITY (NOTE 1)       ---------             ---------
Common stock, par value $684.93;
  Number Shares Authorized 10,000,000;
  Number Shares Outstanding 7,527,485 68,493                68,493
Translation Gain/<Loss> (NOTE 12) <  296,437>           <  137,036>
Retained earnings<Accum deficit>  <1,953,467>           <1,312,457>
                                    ---------             ---------
TOTAL SHAREHOLDERS EQUITY        $<2,181,411>          $<1,381,000>
                                    ---------             ---------
TOTAL LIABILITIES & EQUITY        $   440,725            $  597,412
                                    =========             =========
The accompanying notes are an integral part of these financial statements.



4
                              MEDITECNIC SA
                         STATEMENT OF OPERATIONS
       For the Twelve Months/Year Ending December 31, 2003 and 2002

                                              AUDITED      AUDITED
                                            December 31,  December 31,
                                                2003        2002

REVENUES:
Sales of Products                           $     -0-   $ 183,183
Investment Income                              31,333       2,041
Other Income                                   10,664         -0-
                                              --------    --------
  TOTAL REVENUES                             $  41,997   $ 185,224
                                              --------    --------
OPERATING EXPENSES:
Selling Expenses                            $     -0-   $ 121,820
Salaries                                      237,003     214,960
Social Security Contributions                  33,970      33,878
Interest Expenses/Bank Charges                  2,408       2,453
Loss On Exchange Rates                          6,211          98
Travel Expenses                                31,368      32,133
Trade Exhibition Shows Expense                 10,726      26,556
Representation Fees                            18,576         -0-
Vehicle Expense                                 3,017         -0-
Rent Expense                                   99,637      84,188
Maintenance and Repairs                           463         333
Office Supplies                                 7,119      16,116
Telecommunication Expense                       1,354       3,207
Postage and Mailing Expenses                      827         281
Advertising                                     6,313       4,905
Insurance Expense                               2,931         453
Fees                                           74,271      55,641
Taxes                                           2,235       8,376
Depreciation and Amortization Expenses        144,577     206,685
                                               -------     -------
   TOTAL OPERATING EXPENSES                  $ 683,006   $ 812,083
                                               -------     -------
OPERATING PROFIT <LOSS>                      $<641,009>   <626,859>
OTHER INCOME <EXPENSES>                            -0-    <  3,307>
Rounding differences                          <      1>          1
                                               -------     -------
NET INCOME <LOSS>                            $<641,010>  $<630,165>
                                              ========    ========



5

Per share information:

Basic Income/<Loss> per common share         $<641.01>   $<630.17>
                                               ------      ------
Basic weighted average number
Common Stock shares outstanding               7,527,485   7,527,485
                                              =========   =========

Diluted (loss) per common share  (A)          $<641.01>   $<630.17>
                                               ------      ------
Diluted weighted average number  (A)
Common Stock shares outstanding               7,527,485    7,527,485
(A) There are no stock options cumulative to
      years ended December 31, 2003 and 2002.



The accompanying notes are an integral part of these financial statements

6
                            MEDITECNIC SA
    STATEMENT OF CASH FLOWS FOR 12 MONTHS/YEAR ENDING DECEMBER 31,
	                                          AUDITED    AUDITED
                                                     2003       2002
CASH FLOWS FROM OPERATING ACTIVITIES:
  Income <Loss> From Operations                  $<641,010> $<630,165>
TRANSACTIONS NOT REQUIRING CASH:                   -------    -------
Depreciation Fixed Assets (NOTE 6)                 24,385     48,645
Amortization Capitalized R and D (NOTE 6)         120,192    158,040
                                                   -------    -------
  Total Transactions Not Requiring Cash            144,577    206,685
                                                   -------    -------
CASH PROVIDED <USED> DUE TO CHANGES IN:
Current Assets Decreases <Increases>, and,
Current Liabilities Increases <Decreases>-
  Notes Receivable-Trade                           219,856   <197,105>
  Notes Receivable-Other                             8,805   < 10,760>
  Inventories                                     < 33,822>  < 62,347>
  Unearned Income                                      202   <  6,190>
  Notes and Accounts Payable-Trade                  65,828     21,376
  Notes and Accounts Payable-Other                   1,051   <     22>
  Accrued Liabilities and Prepayments                6,598   <    576>
                                                   -------    -------
   Total Net Change Current Assets/Liabilities     268,518   <255,624>
                                                   -------    -------
    Sub Total                                    $ 413,095  $< 48,939>
                                                   -------    -------
NET CASH PROVIDED<USED> BY OPERATING ACTIVITIES  $<227,915> $<679,104>
                                                  --------   --------
CASH PROVIDED <USED> DUE TO CHANGES IN:
Other Assets Decreases <Increases>, and,
Other Liabilities Increases <Decreases>-
  Acquisition new Vehicle                         < 16,979>       -0-
  Acquisition new Office Furniture                <    -0->  < 51,910>
  New Activities In Capitalized R and D (NOTE 7)  < 36,514>  < 68,194>
  Misc. Other Assets/Liabilities
   Misc. Investments-Refund Cancel Life Insurance   13,261      3,307
                    -Increase Guarantee Deposits  <  2,404>       -0-
                                                   -------    -------
    Sub Total                                     < 42,636> <116,797>
  Shareholders Liability Accounts Incr<Decr>
   Current Debt Liability Account                 < 87,744>       -0-
   Stockholder Long Term Debt Liability Account    429,634    794,515
                                                   -------    -------
CASH PROVIDED<USED> CHANGES OTHER ASSETS/LIABIL. $ 299,254  $ 677,718
                                                   -------    -------
NET CASH INCREASE <DECREASE>                     $  71,339  $<  1,386>
Cash, Beginning of period/Adjusted for Rate Chgs.   10,239     10,565
                                                  --------   --------
Cash, End of period                              $  81,578  $   9,179
                                                  ========   ========

The accompanying notes are an integral part of these financial
  statements.



7

                             MEDITECNIC SA
                    Statement Stockholders' Equity
               Year Ended December 31/Inception to 2003
    UNAUDITED YEARS 1997 THRU 2001; AUDITED YEARS 2003 AND 2002



                                           TRANSLATION ACCUMULATED
                PREF STOCK  COMMON   STOCK  <LOSSES>   EARNINGS
                 SHS $AMT   SHARES   $ AMT   GAINS $  $ (LOSSES)
                ----  ----  ------ -------  --------   ----------

CUM INCEPTION
ACTIVITY THRU
12/31/98 Total    -0-  -0-    100   68,493 <  1,447>   <   2,980>
Equity $64,066    -----------------------------------------------
BALANCE 12/98     -0-  -0-    100   68,493 <  1,447>   <   2,980>
YR 1999<LOSS>                              <  9,147>   < 134,994>
<Deficit $80,075>-----------------------------------------------
BALANCE 12/99     -0-  -0-    100   68,493 < 10,594>   < 137,974>
YR 2000 INCOME                                2,176      129,385
Equity $51,486    -----------------------------------------------
BALANCE 12/2000   -0-  -0-    100   68,493 <  8,418>   <   8,589>
YR 2001 <LOSS>                             <  1,186>   < 673,703>
<Deficit $623,403>-----------------------------------------------
BALANCE 12/2001   -0-  -0-    100   68,493 <  9,604>   < 682,292>
YR 2002 <LOSS>                             <127,432>   < 630,165>
<Deficit$1,381,000>----------------------------------------------
BAL 12/2002       -0-  -0-    100   68,493 <137,036>   <1,312,457>
YR 2003 <LOSS>                             <159,401>   <  641,010>
<Deficit$2,181,411>----------------------------------------------
BAL 12/2003       -0-  -0-    100   68,493 <296,437>   <1,953,467>
=================================================================

These accompanying notes are an integral part of these financial statements.


8
         MEDITECNIC SA (A SWISS CORPORATION)
            Notes to Financial Statements
     For The Twelve Months Ended December 31, 2003

GENERAL:

The condensed consolidated financial statements of MEDITECNIC SA, A Wholly
Owned Subsidiary of MEDITECNIC INC. (a U. S. Corporation) have been prepared
in accordance with the regulations of the Securities and Exchange Commission.
Although certain information normally included in financial statements
prepared in accordance with generally accepted accounting principles has been
condensed or omitted, MEDITECNIC INC. management believes that the disclosures
are adequate to make the information presented not misleading.  The condensed
audited financial statements for the twelve month period ended December 31,
2003 - 2002 should be read in conjunction with the financial statements and
notes thereto included in this report. The condensed consolidated financial
statements included herein reflect all normal recurring adjustments that,in
the opinion of management,are necessary for fair presentation.

The Company commenced operations in the year 1997.

NOTE 1-ORGANIZATION AND BUSINESS PLAN:

MEDITECNIC SA was organized and incorporated in April, 1997, in the Country
of Switzerland, under the name of MEDITECNIC SA. MEDITECNIC SA was incorporated
for the purpose of Medical research and Industrial trade of products in the
medical and industrial domain, including recording and trading of patents;
purchasing of stock equity and management of companies related to their area
of expertise, excluding real assets in the Country of Switzerland.

The Companys articles initially authorized -0- shares of Preferred Stock and
100 shares of Common Stock at a $684.93 par value per share.

As of the date of these financial statements (December 31, 2003 and
2002), there were no shares of Preferred Stock issued or outstanding.
As of the date of these audited financial statements, there are 7,527,485
Shares of Common Stock, issued and outstanding, with a current book value
of $684.93 per share, for a total capitalized value of $68,493.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

The Articles of Incorporation (as revised) authorize MEDITECNIC SA to issue up
to 10,000,000 shares of Common Stock with a par value of $684.93 per share and
-0- shares of Preferred Stock.  As of the year ending December 31, 2003, and
December 31, 2002, there were 7,527,485 shares of Common Stock issued and
outstanding, for a total capitalized stock value of $68,493.  As of
December 31, 2003 and 2002, no Preferred Stock were issued or outstanding.

9
NOTE 2-ACCOUNTS RECEIVABLE:

As of December 31, 2003, total Receivables were $7,594 for VAT (Value
Added Tax) charged to customers at time of shipment.

As of December 31, 2002, total Receivables were $211,806, consisting
of $197,105 in Customer Trade Receivables and $14,701 for VAT (Value
Added Tax) charged to customers at time of shipment.

There are no provisions made for Uncollectible Accounts for either of
the two years covered in these financial statements.  All amounts are
based on actual costs incurred.

NOTE 3-INVENTORIES:

As of December 31, 2003, total Inventories for Raw Materials, Work In
Progress and Finished Goods for resale to customers amount to $103,365.
Included in this amount is a machine suitable for resale to a customer
was rebuilt and placed in inventory.

As of December 31, 2002, total Inventories for the same categories
as stated for year 2003, were $$62,437.

There are no provisions for Write-off of Obsolete or Excess Inventories
for either of the two years covered in these financial statements.  All
amounts are based on actual costs incurred, both for purchased items
and the costs to manufacture items for sales to Customers.

NOTE 4-DEFERRED/UNEARNED INCOME:

As of December 31, 2003, there was $25,438 and $22,987 as of December
31, 2002.  This account is used to collect the adjustment of charges
on the current period for prepaid charges made to customers.

NOTE 5-INVESTMENTS (OTHER):

As of December 31, 2003, the balance is this account was $25,240 for
Deposits of Guarantee and Life Insurance Refund for cancellation of
coverage; the 12/31/02 balance was $32,362 for these items.

NOTE 6 FIXED ASSETS:
The Companys fixed assets consists of the following types/classes of
equipment which are recorded at actual acquisition costs:
           LIFE   AS OF DEC. 31, 2003          AS OF DEC. 31, 2002
ASSET TYPE  YR ORIGINAL COST  ACCUM DEPREC ORIGINAL COST  ACCUM DEPREC
Vehicles     5    $ 16,979      $<  2,315>     $    -0-    $<    -0->
OfficeEquipt 8      22,199       < 11,943>       19,902     <  7,690>
Machinery    5      69,986       < 69,985>       62,744     < 58,905>
DateProcEqpt 5      25,689       < 19,364>       23,081     < 14,343>
             =     -------        -------       -------      -------
TOTALS           $195,775      $<131,196>     $160,295    $< 95,759>
                   =======        =======       =======      =======

Assets are depreciated on a 5 to 8 year useful life basis, calculated
on a declining depreciation method based on the Asset Net Book Value.
All Fixed Assets are revalued every year, from their Net Book Value in
Swiss francs/CHF to US$.

NOTE 7-INTANGIBLE ASSETS/CAPITALIZED RESEARCH AND DEVELOPMENT:

Research and Development Costs are capitalized based on actual costs
incurred.  Amortization is calculated on the Net Book Value of the
Research and Development item/project, and an amortization rate of 33%
(percent) per year.  The balances in these account as of the year end
December 31, 2003 and 2002 are as follows:


                                    As of 12/31/03  As of 12/31/02
Capitalized Research Development      $ 587,819       $ 494,256
Less Accumulated Amortization          <454,888>       <300,061>
                                        -------         -------
NET REMAINING BALANCES               $ 132,931       $ 194,195
                                        =======         =======


NOTE 8-TRADE NOTES AND ACCOUNTS PAYABLE:

These accounts represent the actual costs of amounts due to Vendors
and Suppliers for goods and services received.  The amounts due to
at December 31, 2003 and 2002 were $89,671 and $21,376, respectively.

NOTE 9-STOCKHOLDER CURRENT LIABILITY ACCOUNT:

This account is for collecting costs of advances made to Stockholders
and amounted to $-0- at December 31, 2003 and $78,664.


NOTE 10-PREPAID ACCRUED LIABILITIES:

These costs represent adjustment of charges for the period. The totals
of this account at December 31, 2003 and 2002 were $18,447 and $10,633
respectively.

NOTE 11-LONG TERM LIABILITIES/POSTPONED STOCKHOLDERS LOANS:

The balances in this account as of December 31, 2003 and 2002 were
$2,512,967 and $1,867,749, respectively, consisting of advances from
stockholders which have been postponed. As of the date of these financial
statements, Management at MEDITECNIC SA in Switzerland is of the opinion
that these amounts can be considered as a loss; only a return to a
positive Stockholders Equity could liberate the postponed amounts.








                                            PART II.  OTHER INFORMATION

Item 1.  LEGAL PROCEEDINGS  -  None

Item 2.  CHANGES IN SECURITIES - None

Item 3.  DEFAULTS UPON SENIOR SECURITIES - None

Item 4.  SUBMISSION OF MATTER TO A VOTE OF SECURITY HOLDERS - None

Item 5.  OTHER INFORMATION - None

Item 6.  EXHIBITS AND REPORTS ON FORM 8-K

         Exhibits--None

         Reports on Form 8-K--None.




                                                    SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.


                                                              MEDITECNIC, INC.



Date:     July 21, 2004                                   By:
                                                            Luc Badel
                                                       	    President
                                                  (chief financial officer and
                                                   accounting officer and duly
                                                             authorized officer)


                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350
                             AS ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Meditecnic, Inc. (the
"Company") on Form 10-QSB for the period ended June 30, 2002 as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), each of
the undersigned, in the capacities and on the dates indicated below, hereby
certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, that to his knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material
respects, the financial condition and results of operation of the Company.

By: /s/ Luc Badel	                       Date July 21, 2002
    ------------------------                       ------------
    Luc Badel
    Chief Executive Officer
    Chief Financial Officer







                                 CERTIFICATION
                            PURSUANT TO SECTION 302

I, Luc Badel, certify that:

1. I have reviewed this quarterly report on Form 10-QSB of Meditecnic, Inc.

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

     a) designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this quarterly report is being prepared;

     b) evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this
quarterly report (the "Evaluation Date"); and

     c) presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based on our evaluation
as of the Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent function):

     a) all significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant's ability to record,
process, summarize and report financial data and have identified for the
registrant's auditors any material weaknesses in internal controls; and

     b) any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls; and

6. The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.

Date: July 21, 2004                       By: /s/ Luc Badel
                                                 -------------------
                                                 Chief Executive Officer
                                                 Chief Financial Officer